Smartest Doc
Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors Full Text
Cancer Management and Research, 08/08/2012
Clinical Article
Yim KL – Recent mapping of intracellular signaling pathways promoting tumor proliferation, growth, and angiogenesis has presented mammalian target of rapamycin (mTOR) as a potential target within the phosphatidylinositol 3–kinase–Akt pathway. With the development of the new–generation mTOR inhibitor everolimus, a series of clinical trials over the last 5 years have demonstrated significant benefit in delaying tumor progression.
